Jincheng Pharm's Response to E-cigarette Market Investigation and Development

Business by 2FIRSTS.ai
Apr.11.2024
Jincheng Pharm's Response to E-cigarette Market Investigation and Development
Jincheng Pharm responds to institutional investigation, focusing on e-cigarette materials production amid expanding market and potential industry entry.

On April 9th, Jincheng Pharm (300233.SZ) underwent an investigation by institutions. The company's key executive team personally participated in the reception and provided comprehensive responses to the relevant questions.

 

Jincheng Pharm stated that the company currently only produces raw materials for e-cigarettes and does not directly manufacture finished e-cigarette products. The company has successfully industrialized the synthesis and extraction of nicotine, and is currently expanding its market and monitoring developments in the new tobacco industry. Depending on market conditions, they will decide whether to enter this new sector. Currently, related products are still in the development process.

 

Inquiries from institutions ask: what is the usage rate and market penetration of e-cigarettes? In 2019, 50.4% of American smokers had already used e-cigarettes. In contrast, only 1.2% of Chinese smokers had used them. This indicates that there is a huge potential for development in the Chinese e-cigarette market.

 

In response, Jincheng Pharm stated that they will continue to improve the quality of nicotine used in e-cigarettes to expand market share and brand influence.

 

On the other hand, regarding the shipment of medical nicotine, the company stated that they are currently in communication with customers. Sample products have been shipped and they are awaiting customer confirmation and the next steps for cooperation.

 

Regarding the company's business direction for the second quarter, Jincheng Pharm stated that they will continue to focus on production, operations, and market work based on the trends seen in the first quarter. Additionally, the company's nicotine production will mainly be used in the e-liquid for e-cigarettes.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Imperial Brands Launches £1.45B Buyback Plan as New Product Revenue Jumps 12-14%
Imperial Brands Launches £1.45B Buyback Plan as New Product Revenue Jumps 12-14%
Imperial Brands: FY results in line; launches £1.45bn buyback (to Oct 2026). Constant-currency net revenue to grow low single digits; NGP +12%–14%; adjusted operating profit growth similar to last year’s 4.6%.
Oct.07 by 2FIRSTS.ai
Opinion | Samrat Chowdhery: Tobacco Price Elasticity—A Convenient Myth?
Opinion | Samrat Chowdhery: Tobacco Price Elasticity—A Convenient Myth?
This opinion piece, submitted by Samrat Chowdhery to 2Firsts, challenges the logic of tobacco price elasticity. It argues that high taxes often harm vulnerable populations and fuel illicit markets rather than reducing smoking.
Oct.21
Germany OLG Cologne: Touchscreen Vape Use Violates Driving “Phone Ban”
Germany OLG Cologne: Touchscreen Vape Use Violates Driving “Phone Ban”
Germany’s OLG Cologne ruled that adjusting an e-cigarette touchscreen while driving violates the “phone ban” under road traffic law. The driver, caught changing vape settings on the highway, was fined €150 and received one penalty point, as the court said such actions pose significant distraction risks.
Oct.27 by 2FIRSTS.ai
CNIPA Targets E-Cigarettes as Key Focus in Crackdown on Trademark Violations
CNIPA Targets E-Cigarettes as Key Focus in Crackdown on Trademark Violations
National Intellectual Property Office issued a notice to strengthen management of illegal use of trademarks, promoting fair competition.
Nov.25 by 2FIRSTS.ai
FDA’s Makary on CNN: The Triple Challenge in Vape Regulation — New Opioids, Illicit Trade, and Youth Protection
FDA’s Makary on CNN: The Triple Challenge in Vape Regulation — New Opioids, Illicit Trade, and Youth Protection
In an interview with CNN’s Chasing Life, U.S. Food and Drug Administration (FDA) Commissioner Dr. Marty Makary warned that new health risks — from emerging opioids such as 7-OH to unregulated vaping products — are slipping through regulatory cracks. His remarks reveal the FDA’s growing challenge to balance harm reduction for adult smokers with youth protection and cross-border enforcement.
Oct.10
U.S. Lawmakers Seek to Empower HHS to Destroy Counterfeit Chinese Tobacco Products
U.S. Lawmakers Seek to Empower HHS to Destroy Counterfeit Chinese Tobacco Products
Bipartisan members of the U.S. Congress have introduced the “Ensuring the Necessary Destruction of Illicit Chinese Tobacco Act” (END Act), seeking to amend the Federal Food, Drug, and Cosmetic Act to authorize the Department of Health and Human Services (HHS) to directly destroy adulterated, misbranded, or counterfeit imported tobacco products.Major tobacco companies, including Altria, along with several public health organizations, have announced their support for the bill.
Nov.11 by 2FIRSTS.ai